Competition is expected to intensify as new drugs emerge in the respiratory syncytial virus (RSV) market. Sanofi received approval for its RSV vaccine and is the third company to acquire the approval, following GSK and Pfizer. Furthermore, Moderna’s messenger RNA (mRNA) vaccine awaits the FDA approval. In South Korea, EuBiologics has entered the Phase 1 trial.

According to industry sources on the 20th, the RSV vaccine Beyfortus, developed by Sanofi and AstraZeneca, received approval in South Korea on April 30th. Consequently, Beyfortus has become the first preventative RSV vaccine targeting young children to obtain domestic approval from the regulatory institution. Last year, GSK’s Arexvy an